Navigation Links
Micromet, Inc. Reports Second Quarter 2008 Financial Results
Date:8/7/2008

BETHESDA, Md., Aug. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the second quarter and six months ended June 30, 2008.

Summary of Recent Events:

In June, Micromet and MedImmune presented a clinical update for the BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the International Conference on Malignant Lymphoma in Lugano, Switzerland. All seven patients with relapsed non-Hodgkin's lymphoma treated with blinatumomab at the highest dose level presented at the conference responded to the treatment with partial or complete responses. Responses also appeared to be durable. The most frequent side effects observed so far were lymphopenia, pyrexia and leukopenia. Less common adverse events included transient neutropenia and thrombocytopenia, transient increase of liver enzymes and central nervous system events, all of which were fully reversible. In addition, Micromet and MedImmune commenced treatment of patients with acute lymphoblastic leukemia in a phase 2 clinical trial of blinatumomab.

Also in June, Micromet received a milestone payment of $775,000 from Nycomed in connection with the initiation of formal preclinical safety studies for antibody MT203, which has potential applications in the treatment of inflammatory and autoimmune diseases.

In April, Micromet announced the initiation of the first phase 1 clinical trial with its BiTE antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung cancer and patients with gastrointestinal cancer. MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreatic cancer cells and on cancer stem cells of colon,
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Micromet, Inc. Reports First Quarter 2008 Financial Results
2. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
3. Haemacure Reports Third Quarter 2007 Results
4. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
5. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
6. MDS Reports Third Quarter 2007 Results
7. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
8. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
9. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
10. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
11. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...,, BroadPoliticalEndorsements,Business,andPres...RNewswire-USNewswire/--Onceagain,theNationalBipola...amationendorsingtheir"Safe,tilStable"program,which...sureforbipolardisorder.Today,theNationalBipolarFou...lExpressPriorityMailfromtheLt.GovernorofLouisianaM...
(Date:11/25/2009)...t study follow-up period was too short to draw def...NESDAY, Nov. 25 (HealthDay News) -- In diabetic pa...rs to be no difference in outcomes at one year whe...y with stenting, British researchers report. , ... diabetic patients with coronary artery disease. H...
(Date:11/25/2009)... more positive note, CDC sees few signs of trouble...Nov. 25 (HealthDay News) -- The ongoing H1N1 swine...gerous pneumonias among younger patients, a U.S. h... an increase in serious pneumococcal infections ar...the National Center for Immunization and Respirato...
(Date:11/25/2009)...A drug used to treat colorectal cancer also can re...ered first-line therapy for the disease, researche...this week. , Mntrier,s disease causes thickening ...ea and vomiting, as well as anemia and swelling in... are at increased risk for gastric cancer. Previou...
(Date:11/25/2009)... Initiative expands to incl...for students, teachers, and healthcare professiona... Pleasanton, CA (PRWEB) November 25, 2009 -- Ellu...d social networking solutions that support 21st c...unced today that its Fire and Ice initiative was...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5
...enced by cancer patients undergoing high-dose chem...sea and vomiting caused by the powerful drugs used...for patients. Doctors offer an arsenal of va...ncture involves the insertion of tiny needles at v...
...ness is being collected on a database which both d...ngredient in medical research is the patient's voi...ms, but doctors and researchers could learn a lot ...information on managing their condition. // ...
... treat the neurological problems that are common i... US suffer from kidney failure, which is usually c...n. Kidney failure often leads to neurological comp...ve learned more of the origin of the neurological ...
...overing a gene that may influence the risk of oeso...s helping Cancer Research Campaign scientists lear...hagus. Twenty one members of this family have died...udying 350 members of the extended Liverpool famil...
...s in your diet can affect your vision, according t...MD) is a currently untreatable disease of the eye ...rment. As the name suggests, it gets worse with ag...als aged 55 to 80 with AMD, and compared their die...
...dilation of a blood vessel. This involves all laye...alth due to their potential to rupture, thrombose ...d are the abdominal and thoracic aorta, and brain.... are born with a malformation of a blood vessel wi...
Other Medicine News:
(Date:11/25/2009)...TON,N.J.,Nov.25/PRNewswire-FirstCall/--Pharmasset,...mpanycommittedtodiscovering,developingandcommercia...ancialresultsforthefiscalyearendedSeptember30,2009...h,cashequivalentsandshortterminvestments. ,, P..., Phase2bTrial ,, InlateNovember2009,anind...
(Date:11/25/2009)...WATER,N.J.,Nov.25/PRNewswire/--TheFDAgrantedtradit...,anon-nucleosidereversetranscriptaseinhibitor(NNRT...useintreatment-experiencedadultswhoareexperiencing...andotherantiretroviral(ARV)agents.Thetraditionalap...nasDUET-1andDUET-2.INTELENCEiscurrentlymarketedint...
(Date:11/25/2009)...GRIDGE,N.J.,Nov.25/PRNewswire/--RegadoBiosciences,...romboticaptamerswithactivecontrolagents,announcedt...atthePiperJaffray21stAnnualHealthCareConferenceatt...tationwillbegivenat1:10pm(EST)onTuesday,December1a...mphasisontheleaddevelopmentprogram,theanticoagulan...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 6189 1Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 6189 2Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 6189 3Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 6189 4Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing 6189 5Webcast Alert 3A Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA 6184 1Webcast Alert 3A Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA 6184 2Understanding mechanical properties of silicon nanowires paves way for nanodevices 14797 1Understanding mechanical properties of silicon nanowires paves way for nanodevices 14797 2
... Record system is a family of solutions designed t...entity, longitudinal electronic medical record (EM...to one desktop application that provides access to... record. , By combining all the essential elemen...
EncounterPRO Electronic Health Record
SOAPware The Electronic Health Record
...e efficiency and quality of patient care. It offer...patient information whether it is in text, image, ...cord application, it provides a familiar contempor...icrosoft Office applications. In addition, VersaSu...
Medicine Products: